AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF BETA-CATENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS
申请人:VENKATESAN Aranapakam M.
公开号:US20090004185A1
公开(公告)日:2009-01-01
The present invention relates to amino-substituted quinazoline derivatives as inhibitors of β-catenin/tcf-4 pathway, which can be useful in the treatment of cancer; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.
[EN] AMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS INHIBITORS OF ß-CANTENIN/TCF-4 PATHWAY AND CANCER TREATMENT AGENTS<br/>[FR] DÉRIVÉS DE QUINALOZINE SUBSTITUÉS PAR AMINO EN TANT QU'INHIBITEURS DE LA VOIE B-CATÉNINE/TCF-4 ET AGENTS DE TRAITEMENT DU CANCER
申请人:WYETH CORP
公开号:WO2008086462A2
公开(公告)日:2008-07-17
[EN] The present invention relates to amino-substituted quinazoline derivatives as inhibitors of ß-catenin/tcf-4 pathway, which can be useful in the treatment of cancer; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them. [FR] L'invention concerne des dérivés de quinazoline substitués par amino en tant qu'inhibiteurs de voie b-caténine/TCF-4, qui peuvent être utiles dans le traitement du cancer ; des procédés pour leur préparation ; des compositions pharmaceutiques les renfermant ; et des procédés d'utilisation de ceux-ci.
2,4-Diamino-quinazolines as inhibitors of β-catenin/Tcf-4 pathway: Potential treatment for colorectal cancer
作者:Zecheng Chen、Aranapakam M. Venkatesan、Christoph M. Dehnhardt、Osvaldo Dos Santos、Efren Delos Santos、Semiramis Ayral-Kaloustian、Lei Chen、Yi Geng、Kim T. Arndt、Judy Lucas、Inder Chaudhary、Tarek S. Mansour
DOI:10.1016/j.bmcl.2009.07.070
日期:2009.9
The synthesis and SAR of a series of 2,4-diamino-quinazoline derivatives as beta-catenin/Tcf-4 inhibitors are described. This series was developed by modifying the initial lead 1, which was identified by screening of our compound library and found to inhibit the beta-catenin/Tcf-4 pathway. Replacement of the biphenyl moiety in compound 1 with the N-phenylpiperidine-4-carboxamide chain as in 2, resulted in a number of new analogues, which are potent inhibitors of the beta-catenin/Tcf-4 pathway. Compound such as 16k exhibited good cellular potency, solubility, metabolic stability and oral bioavailability. (C) 2009 Elsevier Ltd. All rights reserved.